Credit Suisse’s Genmab GMAB Stock Holding History

Credit Suisse’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,136	Closed	-$472K	–	3452
2022 Q4	$472K	Sell	11,136 -9,696	-47%	-$400K	﹤0.01%	2824
2022 Q3	$669K	Sell	20,832 -20,540	-50%	-$721K	﹤0.01%	2614
2022 Q2	$1.34M	Sell	41,372 -6,666	-14%	-$216K	﹤0.01%	2184
2022 Q1	$1.74M	Sell	48,038 -21,540	-31%	-$739K	﹤0.01%	2183
2021 Q4	$2.75M	Buy	69,578 +5,598	+9%	+$233K	﹤0.01%	2528
2021 Q3	$2.8M	Buy	63,980 +10,830	+20%	+$486K	﹤0.01%	2548
2021 Q2	$2.17M	Sell	53,150 -204,927	-79%	-$7.91M	﹤0.01%	2804
2021 Q1	$8.47M	Buy	+258,077	New	+$9.71M	﹤0.01%	1693

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Credit Suisse's GMAB Position: Q1 2023 in Review

Credit Suisse sold out of Genmab (GMAB) in Q1 2023, closing a stake of 11,136 shares — an estimated $472K sold.

Credit Suisse first reported a position in GMAB in Q1 2021 and held it in 8 quarters. The position peaked at $8.47M in Q1 2021. 216 funds tracked by Wall St. Rank hold GMAB as of Q1 2023.

Credit Suisse reported no remaining Genmab position as of Q1 2023 after selling out during the quarter.
Credit Suisse sold 11,136 Genmab shares in Q1 2023, an estimated $472K.
Credit Suisse first reported a position in Genmab in Q1 2021 and held it in 8 quarters.
Credit Suisse's Genmab position peaked at $8.47M in Q1 2021.
216 funds tracked by Wall St. Rank held Genmab as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.